Skip Navigation


Rheumatology Advance Access originally published online on November 30, 2004
Rheumatology 2005 44(3):314-317; doi:10.1093/rheumatology/keh488
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
44/3/314    most recent
keh488v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ichiyama, T.
Right arrow Articles by Furukawa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ichiyama, T.
Right arrow Articles by Furukawa, S.
Related Collections
Right arrow Vasculitis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 44 No. 3 © British Society for Rheumatology 2004; all rights reserved

Intravenous immunoglobulin does not increase Fc{gamma}RIIB expression on monocytes/macrophages during acute Kawasaki disease

T. Ichiyama, Y. Ueno, M. Hasegawa, Y. Ishikawa, T. Matsubara and S. Furukawa

Department of Pediatrics, Yamaguchi University School of Medicine, 1-1-1 Minami-kogushi, Ube, Yamaguchi 755-8505, Japan.

Correspondence to: T. Ichiyama, Department of Pediatrics, Yamaguchi University School of Medicine, 1-1-1 Minami-kogushi, Ube, Yamaguchi 755-8505, Japan. E-mail: ichiyama{at}yamaguchi-u.ac.jp

Objectives. Intravenous immunoglobulin (IVIG) therapy has been reported to be effective for reducing the incidence of coronary artery lesions in Kawasaki disease (KD), an acute febrile vasculitis of unknown aetiology. Regarding the mechanism of IVIG in immune thrombocytopenic purpura (ITP), it has been reported that IVIG increases the expression of the inhibitory Fc receptor, Fc{gamma}RIIB (CD32B), on splenic macrophages in a murine ITP model. Regarding the mechanism of IVIG during acute KD, we investigated whether or not IVIG increases the expression of Fc{gamma}RIIB in peripheral blood CD14+ monocytes/macrophages.

Methods. The expression of Fc{gamma}RIIB in peripheral blood CD14+ monocytes/macrophages was determined before and after IVIG therapy in 13 patients with acute KD by flow cytometry.

Results. The percentage of CD14+CD32B+ monocytes/macrophages among peripheral blood mononuclear cells, the absolute number of CD14+CD32B+ monocytes/macrophages and the percentage of CD14+CD32B+ monocytes/macrophages among CD14+ monocytes/macrophages in patients with acute KD before IVIG therapy were significantly increased compared with those after IVIG therapy and in controls. CD14+CD32B+ monocytes/macrophages decreased to within the normal range soon after IVIG therapy.

Conclusions. IVIG therapy in patients with KD did not increase the expression of Fc{gamma}RIIB in peripheral blood CD14+ monocytes/macrophages during the acute stage.

KEY WORDS: Monocytes/macrophages, Kawasaki disease, Fc{gamma}RIIB, Intravenous immunoglobulin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.